StoxJubilant Ingrevia vs Swan Corp: share price & financials comparison
NSE: JUBLINGREA vs SWANCORP · Chemicals · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Jubilant Ingrevia vs Swan Corp at a glance
Jubilant Ingrevia (JUBLINGREA) has a market capitalisation of ₹9,022 Cr, against ₹7,540 Cr for Swan Corp (SWANCORP). Over the past year Jubilant Ingrevia has returned -16.9%, compared with -49.9% for Swan Corp. On valuation, Swan Corp trades at a lower P/E of 10.3 versus 25.7. Jubilant Ingrevia earns a higher return on equity (10.6% vs 9.5%). Jubilant Ingrevia comes out ahead on size, profitability, momentum and technicals. Swan Corp comes out ahead on valuation and financial health. Across the scored metrics below, Jubilant Ingrevia leads on 10 and Swan Corp on 6. On StoxGud's 10-point checklist, Jubilant Ingrevia scores 3/10 and Swan Corp scores 3/10.
| Metric | Jubilant Ingrevia | Swan Corp |
|---|---|---|
| Size | ||
| Market cap | ₹9,022 Cr | ₹7,540 Cr |
| Revenue (latest FY) | ₹4,388 Cr | ₹4,371 Cr |
| Net profit (latest FY) | ₹278 Cr | ₹274 Cr |
| Valuation | ||
| P/E | 25.7 | 10.3 |
| P/B | 2.72 | 0.98 |
| Dividend yield | 0.88% | 0.04% |
| Profitability | ||
| Return on equity | 10.6% | 9.5% |
| Net profit margin | 7.1% | 18.0% |
| Operating margin | 14.2% | -6.0% |
| Growth | ||
| Revenue growth (YoY) | +24.4% | -8.1% |
| Net profit growth (YoY) | +60.4% | — |
| Revenue CAGR (multi-year) | +45.0% | +68.6% |
| Financial health | ||
| Debt to equity | 0.27 | 0.25 |
| Momentum | ||
| 1-month return | -10.9% | -11.5% |
| 1-year return | -16.9% | -49.9% |
| 3-year CAGR | +11.0% | -15.0% |
| 5-year CAGR | -3.1% | +13.5% |
| 10-year CAGR | — | +7.3% |
| Distance from 52W high | -25.1% | -49.6% |
| Technicals | ||
| RSI (14) | 36 | 34 |
| Price vs 200-day avg | -12.9% | -25.7% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Jubilant Ingrevia | Swan Corp |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✗ | ✗ |
| 50-day average above 200-day (uptrend) | ✗ | ✗ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✗ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 3/10 | 3/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Jubilant Ingrevia or Swan Corp?
Jubilant Ingrevia has a market cap of ₹9,022 Cr and Swan Corp has a market cap of ₹7,540 Cr as of 06 Nov 2026.
Which has a lower P/E, Jubilant Ingrevia or Swan Corp?
Swan Corp has the lower P/E: Jubilant Ingrevia trades at 25.7 and Swan Corp at 10.3.
Which gave better returns in the last year, Jubilant Ingrevia or Swan Corp?
Jubilant Ingrevia did better: Jubilant Ingrevia returned -16.9% and Swan Corp returned -49.9% over one year.
Is Jubilant Ingrevia or Swan Corp a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Jubilant Ingrevia scores 3/10 and Swan Corp scores 3/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.